Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A11918 | Pages: 280 | Charts: 66 | Tables: 189 |
The global circulating tumor cells market size was valued at $11.8 billion in 2023, and is projected to reach $43.5 billion by 2033, growing at a CAGR of 13.9% from 2024 to 2033. The major factors driving the market growth are rising prevalence of cancer globally, increasing the demand for early diagnosis and personalized treatment. Furthermore, heightened awareness and investment in cancer research and development, along with the growing focus on liquid biopsy techniques, are propelling market growth. Circulating tumor cells (CTCs) are cancer cells that have detached from the primary tumor and circulate in the bloodstream, potentially leading to the formation of metastases in distant organs. These cells are significant in the context of cancer diagnosis, prognosis, and treatment monitoring because their presence often correlates with disease progression and can provide real-time insights into tumor dynamics. Various methods have been developed to detect and analyze circulating tumor cells, including immunomagnetic separation, microfluidic devices, and molecular assays. Immunomagnetic separation techniques use antibodies attached to magnetic beads to isolate circulating tumor cells based on specific cell surface markers. Microfluidic devices, on the other hand, exploit the size and physical properties of circulating tumor cells to separate them from normal blood cells. Molecular assays, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) , can identify genetic mutations and expressions specific to circulating tumor cells.
Key Market Segments
Key Market Players